Hims & Hers Says Testosterone Outpacing All Drugs Other than Weight-Loss
Dow Jones
Aug 11
1752 ET - Hims & Hers CEO Andrew Dudum says the demand for low-testosterone treatments has the category scaling faster than any other specialty outside of weight loss. Many men are experiencing low testosterone without knowing it, chalking their symptoms up to fatigue or aging, the CEO says in a call with analysts. The company has designed an experience, involving at-home blood collection and treatment that adapts over time, that is resonating with customers, Dudum says. The products' success just three quarters after launch gives management confidence in its ability to expand into injectable and oral TRT before the end of the year, according to Dudum.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.